Articles dans des revues avec comité de lecture (87)
  1. 27. Brenard, E., Pilette, C., Dahlqvist, C., Colinet, B., Schleich, F. N. I. F., Roufosse, F., & Froidure, A. (2020). Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia. Lung, 198(2), 355-360. doi:10.1007/s00408-020-00336-3
  2. 28. Roufosse, F., Kahn, J.-E., Rothenberg, M., Wardlaw, A., Klion, A., Kirby, S. Y., Gilson, M. M., Bentley, J. J., Bradford, E. E., Yancey, S. S., Steinfeld, J., & Gleich, G. (2020). Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. Journal of allergy and clinical immunology. doi:10.1016/j.jaci.2020.08.037
  3. 29. Silva, M., & Roufosse, F. (2019). Oral Corticosteroid Use for the Treatment of Chronic Eosinophilic Disease: A Patient’s and His Physician’s Experience. Advances in therapy, 36(10), 2558-2566. doi:10.1007/s12325-019-01070-w
  4. 30. Khoury, P., Akuthota, P., Ackerman, S. S., Arron, J. J., Bochner, B. B., Collins, M. M., Kahn, J.-E., Fulkerson, P. P., Gleich, G. G., Gopal-Srivastava, R., Jacobsen, E. E., Leiferman, K., Francesca, L. S., Mathur, S. S., Minnicozzi, M., Prussin, C., Rothenberg, M., Roufosse, F., Sable, K., Simon, D., Simon, H.-U., Spencer, L. L., Steinfeld, J., Wardlaw, A., Wechsler, M. M., Weller, P., & Klion, A. (2018). Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD). Journal of leukocyte biology, 104(1), 69-83. doi:10.1002/JLB.5MR0118-028R
  5. 31. Roufosse, F. (2018). Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Frontiers in Medicine, 5(4), 49. doi:10.3389/fmed.2018.00049/full
  6. 32. Roufosse, F., & Johansson, M. M. (2018). Editorial: Pathogenic advances and therapeutic perspectives for eosinophilic inflammation. Frontiers in Medicine, 5(8), 00243. doi:10.3389/fmed.2018.00243
  7. 33. Wechsler, M., Akuthota, P., Jayne, D. R., Khoury, P., Klion, A., Langford, C. A., Merkel, P. P., Moosig, F., Specks, U., Cid, M. M., Luqmani, R., Brown, J., Mallett, S., Philipson, R., Yancey, S. S., Steinfeld, J., Weller, P. F., Gleich, G. J., EGPA Mepolizumab Study Team,, Roufosse, F., et al. (2017). Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England journal of medicine, 376(20), 1921-1932. doi:10.1056/NEJMoa1702079
  8. 34. Garaud, S., Roufosse, F., De Silva, P., Gu-Trantien, C., Lodewyckx, J. N., Duvillier, H., Dedeurwaerder, S., Bizet, M., Defrance, M., Fuks, F., Bex, F., & Willard-Gallo, K. (2017). FOXP1 is a regulator of quiescence in healthy human CD4+ T cells and is constitutively repressed in T cells from patients with lymphoproliferative disorders. European Journal of Immunology, 47(1), 168-179. doi:10.1002/eji.201646373
  9. 35. De Wilde, V., Roufosse, F., & Hermine, O. (2016). Clonal eosinophil and mast cell diseases: different in the same way? Expert Review of Hematology, 9(12), 1107-1109. doi:10.1080/17474086.2016.1254036
  10. 36. Roufosse, F., Heimann, P., Lambert, F., Sidon, P., Bron, D., Cottin, V., & Cordier, J.-F. (2016). Severe prolonged cough as presenting manifestation of fip1l1-pdgfra + chronic eosinophilic leukaemia: A widely ignored association. Respiration, 91(5), 374-379. doi:10.1159/000446076
  11. 37. Bromberg, L., Roufosse, F., Pradier, O., Delporte, C., Van Antwerpen, P., De Maertelaer, V., & Cogan, E. (2016). Methylprednisolone-induced lymphocytosis in patients with immune mediated inflammatory disorders. The American journal of medicine, 7(129), 746-752. doi:10.1016/j.amjmed.2016.02.013
  12. 38. Sauvage, D., Roufosse, F., Sanoussi, I., Massin, M., Rooze, S., De Ville, A., Azzi, N., Huybrechts, S., Dedeken, L., Devalck, C., & Ferster, A. (2015). Treatment-refractory hypereosinophilic syndrome responding to fludarabine in a 12-year-old boy. Leukemia & lymphoma, 56(9), 2711-2713. doi:10.3109/10428194.2014.1003058
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 Suivant >>